Us TOO Logo
Search
  1. Take Actions for Prostate Cancer| Us Too International
  2. Prostate Cancer Knowledge | Hot Sheet Newsletter 2017 | Us Too International

HotSheets by Year

2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001

 

Hot SHEET 2017

Made possible by charitable contributions from

Pfizer
Astellas
BAYER
CyberKnife
 

 - Thank You!

 

Our monthly newsletter, the Hot SHEET, highlights the latest in treatment strategies as well as emerging treatments. The Hot SHEET is distributed free at chapter support group meetings, and is available in PDF on the Us TOO web site.

Hot SHEET Personal Subscriptions Now Available

If you are unable to attend chapter meetings to get the latest issue or prefer an original copy, we can deliver the newsletter right to your home or office. Download and print a subscription order form or order online.



January February March April May June July August September October November December
January | Newsletter | Cover Letter
  • Prostate Cancer Specialists Argue for Early Chemotherapy
  • Outcomes Mostly Similar Between Racial Groups after Prostatectomy
  • Novel Molecule Plus Radiation Kills Prostate Cancer Cells in Mice
  • Intervention Improves Appropriate Imaging in Localized PCa
  • Differences in PSA Production by Benign and Cancerous Tissue
  • Cancer Biomarker Delivers Lethal Drug to Prostate Cancer Cells
  • Doc Moyad’s No Bogus Science: "Glucosamine & Chondroitin?"
  • ADT and Risk of Dementia in Prostate Cancer Patients
  • Doctor Chodak’s Bottom Line
  • Index of Articles Published in the Us TOO Hot SHEET During 2016
February | Newsletter | Cover Letter
  • AUA Consensus Statement Says Use MRI for Prostate Biopsy
  • Incidence of Aggressive Prostate Cancer Diagnoses Declining in US
  • Physicians Continue to See Merits of PSA Testing for Screening
  • HIFU vs. Robotic Prostatectomy to Manage Unilateral Prostate Cancer
  • Inherited Mutations in Three Genes Predict Aggressive Prostate Cancer
  • Doc Moyad's No Bogus Science: "Turmeric/Curcumin Supplements?!"
  • Extraprostatic Extension Rare in Gleason Score 6 Prostate Cancer
  • Light Therapy 'a Huge Leap Forward' for Early Prostate Cancer
  • Effect of Longer vs. Standard Dosing Intervals of Zoledronic Acid
  • Prostate Cancer Patients on AS May Benefit from MRI/Fusion Biopsy
  • Doctor Chodak’s Bottom Line
March | Newsletter | Cover Letter
  • Treat Older Prostate Cancer Patients According to Fitness, Not Age
  • Prostate Cancer Mortality Risk May Depend on Where You Live
  • Why BCRA2-Mutant Prostate Tumors Are So Aggressive
  • 5-Alpha Reductase Inhibitors & Risk of Prostate Cancer Mortality
  • Treatment Duration of Abiraterone Acetate or Enzalutamide
  • Doc Moyad’s No Bogus Science: “Eat Fat to Lose Fat...”
  • USPSTF Names AUA-Nominated Urologist to Review Panel
  • Phase I Trial for Immunotherapy
  • Benefits of MP-MRI in Clinically- Significant Prostate Cancer
  • Risk of Prostate Cancer Diagnosis & Mortality in Men with BPH
  • PSA Nadir May Guide High-Risk Prostate Cancer Care
  • Effect of Short– vs. Long-Term ADT Following Post-RT BCR
  • Doctor Chodak’s Bottom Line
April | Newsletter | Cover Letter
  • In Sunny LA, Prostate Cancer Patients on AS Just Walk Away
  • Low-Fat Meal May Boost Blood Levels of Costly Cancer Drug
  • Single Dose of Brachytherapy May Be an Effective Treatment
  • Targeted Biopsy to Detect Gleason Score Upgrading During Active Surveillance
  • Exploring Optimal Sequence of Abiraterone & Enzalutamide
  • Doc Moyad’s No Bogus Science: “Exercise & Drugs for CRF”
  • Urine Assay for Detecting PCa 3 Genomic Testing Predicts Metastasis & Mortality in Prostate Cancer
  • Blocking Enzalutamide Resistance in Men with Prostate Cancer
  • Researchers Link New Mutation to Prostate Cancer Risk in Black Men
  • Blood Test Instead of Biopsy for Metastatic Prostate Cancer
  • PSA Nadir May Guide High-Risk Prostate Cancer Care
  • Effect of Short– vs. Long-Term ADT Following Post-RT BCR
  • Doctor Chodak’s Bottom Line
May | Newsletter | Cover Letter
  • USPSTF Backs Individualized Prostate Cancer PSA Screening
  • Updated Guideline on Brachytherapy in Prostate Cancer
  • Vessel-Sparing RT Preserves Erectile Function in Prostate Cancer
  • Post-RP BCR-Free Survival After Grade Reclassification on AS
  • Urologists vs. Radiation Oncologists on High-Risk Prostate Cancer
  • Men Uncertain About Benefits & Risks of Active Surveillance
  • Doc Moyad’s No Bogus Science: "Vitamin D & VITAL Results"
  • Intermediate-Term Outcomes from AS According to Recurrence Risk
  • Prognostics Significance of a Negative Prostate Biopsy
  • Magnetic Resonance Imaging in Diagnosis of Prostate Cancer in Patients with PSA Level 2-10 ng/mL
  • Doctor Chodak’s Bottom Line
June | Newsletter | Cover Letter
  • AR-V7 mRNA & Castration-Resistant Prostate Cancer Outcomes
  • First Guide to Second-Line Hormonal Therapy for Prostate Cancer
  • Black Men Should be Screened Earlier for Prostate Cancer
  • Relative Toxicities: Intermittent vs. Continuous Androgen Deprivation
  • PSA Testing Rates Leveling Off
  • Doc Moyad’s No Bogus Science: “Aspirin is Having a Good Year!”
  • Predicting Post-RP Metastases Using the Decipher® Test
  • Multimodal Treatment for Early-Stage Metastatic Prostate Cancer
  • Re-Examining PSA Density for Predicting Prostate Cancer
  • Structure-Based IsoPSA Assay Outperforms PSA Concentration
  • QIAGEN to Market Liquid Biopsy to Detect AR-V7 mRNA in Blood
  • Doctor Chodak’s Bottom Line
July | Newsletter | Cover Letter
  • LATITUDE: Randomized Trial of ADT With and Without Abiraterone
  • Prostate Cancer Surveillance Works for Younger Men
  • Adding Abiraterone to Standard Treatment Improves Survival
  • TMPRSS2:ERG and PCA3 RNA Tests for Aggressive PCa
  • MRI Accuracy for Prostate Cancer Challenged
  • Doc Moyad’s No Bogus Science: “Testosterone & Weight Loss?!”
  • African American and Caucasian Men Receiving Sipuleucel-T
  • Aggressive Variant CRPC Predicts Platinum Sensitivity
  • Web-Based Stress Management for Newly Diagnosed Cancer Patients
  • RT + ADT for 18 Months May Be Sufficient in High-Risk PCa
  • One RT Dose May Be Enough
  • Doctor Chodak’s Bottom Line
August | Newsletter | Cover Letter
  • Poor Responders Benefit from Taxane Switch
  • Prostate Cancer Treatment-Related Factors Differ in Black, White Men
  • Negative Confirmatory Biopsy a Good Sign in Prostate Cancer AS
  • RP Innovation and Outcomes at Military and Civilian Institutions
  • PCa Screening Benefits Depend on View of Treatment Side Effects
  • Doc Moyad’s No Bogus Science: “Beware of the Nocebo?!”
  • Some Younger Men with Prostate Cancer are Candidates for AS
  • Genomic Test Can Predict Prostate Cancer Metastases After Surgery
  • PET CT May Show Treatment Outcome Early in Metastatic CRPC
  • Post-RP Radiotherapy Benefits Selected Men with Elevated PSA
  • Doctor Chodak’s Bottom Line
September | Newsletter | Cover Letter
  • Surgery for Early Prostate Cancer May Not Save Lives 
  • Cabazitaxel Does Not Prolong Overall Survival in Metastatic PCa 
  • Adverse Pathologic Findings in Low- Volume Intermediate-Risk PCa 
  • Treatment Regret Not Common in Prostate Cancer Survivors 
  • Radium-223 Dichloride Safe Long- Term in Metastatic Prostate Cancer 
  • Doc Moyad’s No Bogus Science:  “Jack-Moyad Patient PSA Choice?!” 
  • With PSA Screening, Physicians Practice What They Preach 
  • Life with Sexual Dysfunction after Prostate Cancer Treatment Study 
  • Doctor Chodak’s Bottom Line 
  • Opdivo, Rubraca Combination Studied in Prostate, Other Cancers 
October | Newsletter | Cover Letter
  • New Look at Old Data Confirms Mortality Benefit of PSA Screening 
  • Two New Treatments Are Equally Beneficial for Metastatic CRPC 
  • Reduced Cabazitaxel Dose after Docetaxel Effective in CRPC 
  • Immediate vs. Delayed ADT for Asymptomatic Non-Curable PCa 
  • Doc Moyad’s No Bogus Science: “So What about Lifestyle Changes?” 
  • Critical Comparison of Techniques for MRI-Targeted Prostate Biopsies 
  • African American Men with Low-Risk PCa are Candidates for AS 
  • Can We Stop Monitoring PSA 20 Years after Radical Prostatectomy? 
  • ADT and Heart Failure in Men with Localised Prostate Cancer 
  • Bone Health & Bone-Targeted Therapy in Localized Prostate Cancer 
  • Adjuvant RT for Positive Surgical Margins Post-Prostatectomy 
  • Life Insurance and Primary Treatment 6 for Prostate Cancer 
  • Doctor Chodak’s Bottom Line
  • $1.5 Million Prostate Cancer Grant 
November | Newsletter | Cover Letter
  • Prostate Cancer Patients Offered the Lure of Robotic Surgery
  • Long-Term Data Confirm Quality of Life Benefits with SpaceOAR Hydrogel
  • Axumin PET/CT Scans & Treatment Plans in Men with Suspected BCR
  • Predicting the Probability of Lymph Node Invasion Using Sentinel Node
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and Prostate Cancer
  • Doc Moyad’s No Bogus Science: "Melatonin Fights Prostate Cancer!?"
  • Prostate Cancer Patients Unclear on Differences among Treatments
  • Cardiovascular Risk with ADT: GnRHa Injections vs. Bilateral Orchiectomy
  • Genomic Testing for Localized Prostate Cancer—What's Next?
  • Retreatment with Radium-223
  • Influence of Prednisone on the Efficacy of Cabazitaxel
  • Low-Dose Brachytherapy for Low-Risk Prostate Cancer: Long-Term Results
  • Doctor Chodak's Bottom Line
December | Newsletter | Cover Letter
  • Higher PSA Levels Found at Metastatic Prostate Cancer Diagnosis
  • Nerves & Prostate Cancer Growth
  • Cancer Can Change Tissue That Surrounds It – UCSF Study Finds
  • Patterns of PSA Test Use in the U.S., 2005 to 2015
  • Utility of Digital Rectal Exam As an Adjunct to PSA in Cancer Detection
  • Intermittent Auricular Electroacupunc- ture – Pilot Study for Hot Flashes
  • Doc Moyad’s No Bogus Science: “IV Vitamin C Fights Cancer? What?!”
  • Harm Seen in Alternative Treatments
  • Stereotactic Body RT for Low - Risk Prostate Cancer – 10 - Year Analysis
  • Prostate Cancer Diagnosis and Treatment Decision - Making & QoL
  • High Dose Rate Brachytherapy as Monotherapy for Localized PCa
  • Doctor Chodak’s Bottom Line

CLICK HERE and opt-in to receive free educational emails from Us TOO.

Opt In